Document:

Exhibit 10.34

Summary Description of Named
Executive Officer

Oral At-Will Employment Agreement

With
the exception of Ginger L. Graham, our Chief Executive Officer and Daniel M.
Bradbury, our President and Chief Operating Officer with whom we have written
employment agreements, we maintain oral at-will employment relationships with
each of our named executive officers: Alain D. Baron, M.D.,  Mark G. Foletta, and Orville G. Kolterman,
M.D. Each of these executive officers receives our normal and customary
employment benefits, generally on the same terms as all of our employees. The
benefits include the right to (i) participate in our 401(k) Plan and our
Employee Stock Purchase Plan, and (ii) receive stock option grants under our
Equity Incentive Plan and cash bonuses under our cash bonus plan. The cash
bonus plan is called the Executive Cash Bonus Plan when it applies to those
employees with the title of executive director or above. Each of these
executive officers is also eligible, along with all of our employees holding
the title of vice-president and above, to participate in our Deferred
Compensation Plan and our Change in Control Employee Severance Benefit Plan.
The Change in Control Plan provides each participant with certain benefits in
the event such employee ceases employment with Amylin without cause or under
certain specified circumstances and within 90 days prior to, or within 13
months following specified change of control transactions.  An eligible
employee will receive continuation of salary for 18 months (24 months in the
case of the president, chief executive officer or chief operating officer) in
normal regular monthly installments and any bonus such employee would otherwise
have received under our annual cash bonus plan.  We also have customary
indemnification agreements with our officers, including these executive
officers. In addition, the Compensation and Human Resources Committee of our
Board of Directors reviews the salaries of our executive officers from time to
time.  Ms. Graham’s annual salary is currently set at $565,000. Dr. Baron’s
annual salary is currently set at $375,380, Mr. Bradbury’s annual salary is
currently set at $480,000, Mr. Foletta’s annual salary is currently set at
$315,000, and Dr. Kolterman’s annual salary is currently set at $375,380.Exhibit 10.40

***Text Omitted and Filed Separately

with the Securities and Exchange Commission

Confidential Treatment Requested

Under 17 C.F.R. Sections 200.80(b)(4) and 240.24b-2.

C  O  N  F  I
D  E  N  T  I  A  L

COMMERCIAL
SUPPLY AGREEMENT

THIS SUPPLY AGREEMENT (the “Agreement”)
is entered into as of October 12, 2006 (the “Effective
Date”), by and between AMYLIN
PHARMACEUTICALS, INC. (“Company”),
having its principal place of business located at 9360 Towne Centre Drive,
Suite 110, San Diego, CA 92121, U.S.A., and Wockhardt UK (Holdings) Ltd. (“Manufacturer”), having its
registered office at Ash Road North, Wrexham Industrial Estate, Wrexham LL13
9UF, United Kingdom.

RECITALS

WHEREAS, Manufacturer is in the business of
manufacturing pharmaceutical products;

WHEREAS, Company is engaged in research,
development, and commercialization of pharmaceutical products; and

WHEREAS, Company and Manufacturer (then CP
Pharmaceuticals Ltd) having previously entered into a Manufacturing Agreement,
effective from 28th April 1999 and now mutually wish to supercede
such agreement with the terms and conditions set forth herein; and

WHEREAS, Company wishes to purchase from
Manufacturer, and Manufacturer is willing to manufacture and supply to Company,
the Product (as defined below) in commercial quantities for commercial sale on
the terms and conditions set forth herein.

NOW, THEREFORE, in consideration of the foregoing and
the mutual covenants and premises contained in this Agreement, the parties
hereto agree as follows:

1.             Definitions.

1.1          “Affiliate” shall mean an entity that, directly or
indirectly, controls, is controlled by or is under common control with a party,
where “control” means the possession, direct or indirect, or the power to
direct or cause the direction of the management or policies of an entity,
whether by ownership of at least 50% of the common stock or voting ownership
interest of an entity, by contract or otherwise.

   
 

 CONFIDENTIAL

1.2          “Applicable Laws” shall mean all United States and
European jurisdiction’s federal, state, local and other laws, statutes, rules,
regulations, ordinances, (including any amendments thereto), applicable to the
manufacture and shipment of Product, including, without limitation, the
applicable regulations and guidance of the FDA, all applicable EU cGMPs. Extensions
to the aforementioned defined territories shall be the subject of side letters
to this Agreement which may be jointly agreed in good faith from time to time
between the parties.

1.3           “Batch” shall mean that quantity of units of
Product produced from a single homogeneous mix in a single cycle of
manufacture.

1.4          “Batch Record” shall mean Manufacturer’s documented
procedures for compounding, filling, testing, labeling, and packaging
Pramlintide Acetate Drug Substance and/or inactive excipients into Product as
agreed upon by the parties in writing in advance of manufacture of the
applicable Batch.

1.5          “Business Day” shall mean any Monday, Tuesday,
Wednesday, Thursday or Friday which is not a bank holiday in San Diego,
California or the United Kingdom.

1.6          “Certificate of Analysis” shall mean a signed certificate, issued
by the party providing a pharmaceutical compound or product, attesting to the
nature and/or content, as applicable, of such compound or product.

1.7          “cGMP” shall mean current good manufacturing
practices as defined from time to time (a) in regulations promulgated
under the FDCA; (b) the principles and guidelines specified in Chapter II
of European Commission Directive 91/356/EEC, including “the rules governing
medicinal products” in the European Union Volume 4; and (c) laws, rules,
or regulations of an applicable Regulatory Authority at the time of manufacture
equivalent to those in (a) and (b) above.

1.8          “Confidential Information” of a party shall mean all data and
information, tangible or intangible, whether in written, graphic, verbal or
electronic form, disclosed by such party to the other party, its employees or
representatives, or developed for or on behalf of such party by the other party
under this Agreement.

1.9          “Contaminant” means a substance contained in Product
that (i) causes Product to fail to meet any Product Requirements or (ii) causes
Product to be adulterated within the meaning of the FDCA.

1.10        “Control” shall mean, with respect to certain
rights, possessing ownership of or possessing the right to grant a license to
such rights.

1.11        “Drug Approval Application” shall mean an application and/or
supplemental application for Regulatory Approval required before commercial
sale or use of Product as a drug in a regulatory jurisdiction.

1.12          “Facilities”
shall mean the manufacturing plant and offices owned by Manufacturer and
located at Ash Road North, Wrexham Industrial Estate, Wrexham LL13 9UF,

 2
 

 CONFIDENTIAL

United Kingdom and
a storage and distribution facility owned by Manufacturer and located at Unit
B, Spectrum Business Park, Bridge Road South, Wrexham Industrial Estate,
Wrexham LL13 9QA, United Kingdom.

1.13        “FDA” shall mean United States Food and Drug
Administration or any successor agency.

1.14        “FDCA” shall mean the United States Federal
Food Drug and Cosmetics Act, as amended, and all regulations promulgated
thereunder, or any successor laws and regulations thereto

1.15        “Fill Date” shall mean that date on which the
manufacture of a Batch is actually completed, notwithstanding the date on which
the Batch manufacture begins.

1.16        “Hidden Defect” shall mean a defect that causes Product
to fail to conform to the Specifications or to the warranties provided by
Manufacturer hereunder, which defect is not discoverable upon reasonable
physical inspection and testing performed pursuant to Section 5.3 but is
discovered at a later time (e.g., in the
course or as a result of long-term stability studies).

1.17        “Launch Date” shall mean the date of the first
commercial sale of Product manufactured using Manufacturer Technology under
this Agreement, in a country after approval by appropriate regulatory
authorities for market and sale in such country.

1.18         “Manufacturing Process” shall mean any and all specifications,
compositions, identities and quantities of materials, formulas, methods,
techniques, processes, procedures and quality control necessary or relevant for
manufacture of Product.

1.19        “Manufacturer’s
Technology”
shall mean the specific and confidential technology which has been developed by
Manufacturer for the siliconisation of glass cartridges used in the production
of the Product as defined herein and is described further in related standard
operating procedures (“SOPs”) .

1.20        “Materials” shall mean raw materials, components,
excipients and other ingredients and packaging materials used in the
manufacture and packaging of Product.

1.21        “OUS Country” shall mean any country outside of the
United States and its territories.

1.22        “Pramlintide
Acetate or Pramlintide Acetate Drug Substance”
shall mean a dry bulk powder preparation containing pramlintide acetate peptide
as provided by Company for further manufacture into Product by Manufacturer.

1.23        “Product” shall mean the finished dosage form of
Pramlintide Acetate, for injection in cartridge presentation as described in Exhibit B to this Agreement.

1.24        “Product Price” shall mean the price for Product set
forth in Exhibit A.

 3
 

 CONFIDENTIAL

1.25        “Product Requirements” shall mean all of the requirements
referenced in Section 8.3 of this Agreement.

1.26        “Quality Agreement” shall mean the (Technical) Quality
Agreement between Company and Manufacturer dated as of October 16, 2002, or
that agreed in writing on any subsequent date between the parties, which is
incorporated into this Agreement by reference and made a part hereof.

1.27        “Recall
Action” shall have the meaning ascribed to it
in Section
5.4 hereof.

1.28        “Regulatory Approval” shall mean any approvals (including
supplements, amendments, pre-marketing and post-marketing approvals, labeling
approval, and pricing and reimbursement approvals), licenses, registrations or
authorizations of any national, supra-national (e.g., the European Commission or the Council of the European
Union), regional, state or local regulatory agency, department, bureau,
commission, council or other governmental entity, necessary for the
manufacture, distribution, use or sale of Product in a regulatory jurisdiction.

1.29        “Regulatory Authority” shall mean the FDA in the United States
or the MHRA, EMEA or any other applicable regulatory agency or entity having
the responsibility, jurisdiction, and authority to approve the manufacture,
use, importation, packaging, labeling, marketing, and sale of Product in any
additional country, or any successor body to any of them.

1.30        “Specifications” shall mean the regulatory,
manufacturing, quality control and quality assurance procedures, processes,
practices, standards, instructions and any other attributes that the parties
agree upon, or that are otherwise required, in connection with the manufacture
of Product, as set forth on Exhibit B, as
amended from time to time by written agreement of the parties pursuant to
Section 4.3.

1.31        “Term” shall have the meaning provided in
Section 9.1.

2.             Purchase
and Supply.

2.1          Purchase and Supply Agreement. 
During the Term, Company agrees to buy from Manufacturer, and
Manufacturer agrees to sell to Company, such quantities of the Product as may
be set forth on purchase orders placed by Company in accordance with the
provisions hereof.

2.2          Minimum Orders. 
For the time frame beginning on the Effective Date and ending on the
first day of the calendar month after the date of the one year anniversary of
the date of the first Regulatory Approval of the Product (the “Initial Period”), Company shall
only be obligated to purchase, and Manufacturer
shall only be obligated to supply, that quantity of Product ordered by Company,
which is submitted to Manufacturer via purchase order and Manufacturer accepts
via a confirmation.   For the time frame beginning on the date
the Initial Period ends and ending on the one year anniversary thereof (the “Second Period”), Company agrees to
purchase Product from Manufacturer in an amount equal to or greater than [***]

***CONFIDENTIAL
TREATMENT REQUESTED

 4
 

 CONFIDENTIAL

cartridges. For
the time frame beginning on the date the Second Period ends and ending on the
one year anniversary thereof (the “Third Period”),
Company agrees to purchase Product from Manufacturer in an amount equal to or
greater than [***] cartridges. For the time frame beginning on the date the
Third Period ends and ending on the one year anniversary thereof (the “Fourth Period”), Company agrees to
purchase Product from Manufacturer in an amount equal to or greater than [***]
cartridges. For the time frame beginning on the date the Fourth Period ends and
ending on the one year anniversary thereof (the “Fifth
Period,” and together with the Initial Period, the Second Period, the Third
Period, and the Fourth Period,  the “Purchase Periods”), Company
agrees to purchase Product from Manufacturer in an amount equal to or greater
than [***] cartridges.  Not withstanding
the foregoing, however, the Parties agree that upon completion of the Initial
Period, the Parties shall meet for the purpose of reconsidering each of the
foregoing quantities specified for the Third, Fourth and Fifth Periods and
shall, prior to the commencement of the Third Period, adjust such quantities,
if necessary, upon mutual written agreement. 
In the event that during any Purchase Period the Company’s actual
purchases of the Product from Manufacturer are less than the minimum amount
specified above for said Purchase Period, Company will pay to Manufacturer the
difference between the amount invoiced to Company for its actual purchases
during the Purchase Period and the amount that would have been invoiced had
Company purchased the minimum amount agreed to for such Purchase Period; provided, however, (i) Company shall not be
obligated to make any such payments if the Agreement has been terminated, and
(ii) the Company shall only be obligated to pay for Product supplied to the
Company pursuant to this Agreement.  In
any given calendar quarter, Company shall order [***]% of the minimum quantity,
plus or minus [***]%, for the Purchase Period in which the calendar quarter
occurs.  Following the Fifth Period,
Manufacturer may bid, in competition with Company’s other manufacturers of the
Product, to provide a greater percentage of Company’s requirements of the
Product.  For purposes of this Section
2.2, a “purchase” shall mean the submission by Company of a firm purchase
order.

2.3          Forecasts. 
Beginning within seven (7) days after the Effective Date and at the
commencement of every calendar month thereafter, Company shall furnish
Manufacturer with non-binding forecasts of [***] Product requirements under
this Agreement for the ensuing [***] calendar [***].

2.4          Purchase Orders. 
Company shall order the Product by submitting written purchase orders,
in Company’s standard form in effect from time to time, to Manufacturer.  Each purchase order shall specify the
quantities of the Product ordered which shall be in Batch quantities or
multiples thereof, the cartridge size thereof, the desired shipment date for
such Product, the pricing, and any special shipping instructions.  Company shall submit each purchase order to
Manufacturer at least [***] Business Days in advance of the desired shipment
date specified in such purchase order. No more than ten (10) Business Days
following receipt of each purchase order Manufacturer shall confirm in writing its
acceptance of same and shall advise Company of its planned shipment date and
its designated lot numbers for the Product. 
Manufacturer shall make each shipment of the Product in the quantity,
cartridge size and on the shipment date specified for it on Company’s purchase
order, via the mode(s) of transportation and to the party and destination
specified on such purchase order. 
Release samples representing the Manufacturing Process and meeting the
requirements set forth in the Batch Record will be shipped within [***]
Business Days after the actual Fill Date.

***CONFIDENTIAL
TREATMENT REQUESTED

 5
 

 CONFIDENTIAL

Manufacturer shall
ship the Product which is the subject of the purchase order, subject to Section
5.1, and shall supply copies of the associated documentation as described in
the Quality (Technical) Agreement, including the signed Certificate of Analysis
and signed certificate of compliance for the Product. Any purchase orders for
the Product submitted by Company to Manufacturer shall reference this Agreement
and shall be governed exclusively by the terms contained herein except to the
extent set forth in the following sentence. The terms and conditions of this
Agreement shall supersede any term or condition in any order, confirmation or
other document furnished by Company or Manufacturer that is inconsistent with
these terms and conditions, except to the extent that any term, provision or
condition set forth in a purchase order expressly states that it supersedes any
term, provision or condition of this Agreement, unless it is mutually agreed between the parties hereto.  If purchase orders are issued less than [***]
Business Days in advance of the desired shipment date, Manufacturer shall make
commercially reasonable efforts to meet Company’s requirements, however Manufacturer’s
failure to meet such requirements shall not be deemed to be a breach of this
Agreement.  In the event a purchase order
is issued less than [***] Business Days in advance of the desired shipment
date, Manufacturer shall advise Company within [***] Business Days whether such
purchase order can be fulfilled by the date requested in the purchase order and
the parties shall agree upon a delivery date of the requested Product.

3.             Prices
and Payment.

3.1          Product Price. 
The Product Price shall be fixed for the Initial Period of this
Agreement as specified in Exhibit A.

3.2          Purchase Price Adjustment. 
Upon expiration of the Initial Period, Manufacturer may adjust the
Purchase Price of Product to reflect changes in [***], subject to Section
4.1(b). Any such adjustment by Manufacturer shall be notified to Company no
less than [***] prior to expiration of the Initial Period.  Upon commencement of the Second Period
Company and Manufacturer agree to meet [***] to formally review continuous
improvement activities and other improvements resulting from experience in
operating the Manufacturing Process including [***]. Company and Manufacturer
shall work together to obtain process improvements.  Net savings or increases in the [***] shall
result in reductions or increases respectively in the Purchase Price. [***]
resulting from Manufacturer’s efficient management of the Manufacturing Process
shall not result in reductions in the Purchase Price. Net increases in the cost
of the Manufacturing Process due to [***] shall result in increases in the
Purchase Price. Net savings in the product cost per unit achieved due to
increases in the [***] shall result in corresponding reductions in the Purchase
Price.  If the parties cannot in good
faith agree on the proposed Purchase Price adjustment, the dispute will be
discussed between the senior management of both Company and Manufacturer.  In no event may Manufacturer increase the
Purchase Price following the Initial Period by [***].  The increase will be applicable on [***] of
every calendar year.

3.3          Invoices. 
Upon acceptance by Manufacturer of a purchase order, Manufacturer shall
invoice Company for [***]%) of the estimated aggregate Product Price for the
purchase order (the “Reservation Fee”). 
Not withstanding the foregoing, however, the Parties agree that prior to
completion of the Initial Period, the Parties shall meet for the purpose of
reconsidering the percentage used to determine the Reservation Fee and shall,
prior to the

***CONFIDENTIAL
TREATMENT REQUESTED

 6
 

 CONFIDENTIAL

commencement of
the Second Period, adjust such percentage, if necessary, upon mutual written
agreement. Upon completion of the manufacture of each purchase order  and the submission of a Certificate of
Analysis and Certificate of Compliance duly approved by Manufacturer to Company
for the batches of Product manufactured for such purchase order Manufacturer
shall refund Company the Reservation Fee and invoice Company the Product Price
for the quantity of Product manufactured.

3.4          Cancellation Fee. If, after issuing a Purchase Order to
the Manufacturer for quantities which are in excess of  the minimum order quantities defined in
Section 2.2 for that Purchase Period and acceptance by the Manufacturer of such
Purchase Order, but before Manufacturer starts work to manufacture for that
Purchase Order, the Company subsequently cancels or postpones its order, then
Manufacturer shall have the right but not the obligation to charge to Company
[***]%) of the product price (“Cancellation Fee”). If, after issuing a Purchase
Order to the Manufacturer, the Company subsequently cancels or postpones its
order after the Manufacturer has started work to manufacture for that Purchase
Order, the Manufacturer shall be entitled to charge to Company [***]%) of the
Product Price for that Purchase Order.

3.5          Time for payments shall be of the
essence. The
Manufacturer reserves the right to charge the lesser of either [***]% or the
highest percentage allowed under applicable law, per month on any overdue
amount until the date of payment in full save where part or whole payment is
withheld by the Company on a specific invoice as a result of a genuine dispute
over that invoice or part thereof.

3.6          Method of Payment; Currency. All payments due hereunder to
Manufacturer shall be paid to Manufacturer in [***] not later than [***] days
following the receipt of the applicable invoice, unless such shipment of
Product is rejected in accordance with the provisions of Section 5.3.  Company shall make payment by telegraphic
transfer to the account number 02140934 at HSBC., 17-19 Regent Street, Wrexham,
LL11 1RY, UK, Sort Code 40-47-26 or to such other account of Manufacturer
designated in writing to Company.  All
currency amounts referenced in this Agreement are to [***].

3.8          Effect of Certain Events. 
In the event of termination or expiration of this Agreement,
Manufacturer shall provide reasonable assistance to Company to implement the
transfer of manufacturing responsibility for the Product to Company or its
designee.  Such reasonable assistance
shall include transfer of the Manufacturing Process as described in
Section 7.7 but always with the exception of Manufacturer Inventions
subject to Section 7.2. In the event of termination of this Agreement by
Company pursuant to Section 9.2(a) or (b) or 9.3(c), such reasonable
assistance will be provided at Manufacturer’s expense. In the event of any
other termination or expiration of this Agreement, Company shall pay
Manufacturer’s reasonable and documented costs of providing such
assistance.  In the event of termination
or expiration of this Agreement, Manufacturer will promptly return to Company
all unused Pramlintide Acetate Drug Substance provided to Manufacturer pursuant
to Section 4.1 hereof and Materials paid for by Company as directed by and at
the expense of Company.

***CONFIDENTIAL
TREATMENT REQUESTED

 7
 

 CONFIDENTIAL

4.             Manufacturing.

4.1          Materials.

(a)           Except as stated in Section 4.1(b), Manufacturer will
obtain any Materials with the exception of Pramlintide Acetate Drug Substance
required for the manufacture of the Product, in reasonable quantities
consistent with Company’s most recent forecast for the Product. All Materials
obtained by Manufacturer pursuant to this Section 4.1(a) shall meet the
specifications stated in the Quality Agreement and Manufacturer shall order all
Materials only from vendors approved in advance by Company.  Manufacturer shall ensure all Materials
required to manufacture the Batch are released for use, in accordance with
Manufacturer’s quality system and requirements stated in the then current
Quality Agreement, prior to the manufacturing of the Batch. Company shall
reimburse the Manufacturer all the costs of all the Materials in stock or on
order on behalf of the Company by the Manufacturer, including QC testing costs
and disposal costs, if such Materials become redundant at any time if: (i)
Company makes a good faith determination not to continue with the
commercialization of Product, (ii) Company terminates this Agreement according
to Section 9.3(a), (iii) such materials expire due to insufficient demand for
Product, or (iv) such materials become obsolete due to a change of
specification advised by the Company; provided,
however, Manufacturer
shall use commercially reasonable efforts to either utilize such materials in
other areas of its business or to return the materials, and Company shall not
reimburse Manufacturer for any such utilized or returned materials.  The orders of Materials will be placed
keeping in view the future forecasts and delivery lead times. Manufacturer will
maintain a safety stock level of at least [***] calendar [***], but no more
than [***] calendar [***] of approved Materials unless the minimum procurement
quantity for any Material provides sufficient stocks for greater than [***]
calendar [***].  For clarification purposes,
safety stock includes Materials needed to fulfill forecasts issued by Company
pursuant to Section 2.3.  Manufacturer
and Company will review safety stock levels on a quarterly basis and will
mutually agree to make appropriate changes.

(b)           Company shall supply to Manufacturer, free of charge,
freight and duties prepaid and with transportation insurance paid by Company,
quantities of Pramlintide Acetate and Pramlintide Acetate reference standard
sufficient to enable Manufacturer to manufacture and perform agreed analytical
testing of the quantities of the Product ordered by Company.  Pramlintide Acetate will be sampled according
to the Quality Agreement and held by Manufacturer under appropriate storage
conditions until such time as it is required for manufacture of Product.
Manufacturer and Company agree that in the case of Product manufactured prior
to satisfactory completion of the first [***] commercial full scale batches
(including the process validation batches) of each of the presentations of Product,
Manufacturer shall make commercially reasonable efforts to maximize yields but
shall not be held liable for losses of Pramlintide Acetate occurring as part of
the Manufacturing Process. After satisfactory completion of the first [***]
commercial full scale batches of each Product the parties shall meet to agree
to a target yield for future production (Target Yield). The Target Yield shall
be defined as at least [***]%)] of the average yield of the first [***] batches
of each presentations of Product. For clarity, “satisfactory completion” of a Batch will not include a Batch
with aberrant results.  All shipments of
Pramlintide Acetate will be accompanied by a Certificate of Analysis indicating
the peptide content of such Pramlintide Acetate and such other information as
Company may specify and is to arrive approximately thirty (30) days in advance
of planned

***CONFIDENTIAL
TREATMENT REQUESTED

 8
 

 CONFIDENTIAL

Product
manufacture to allow for testing. Within fifteen (15) business days of receipt
of any Pramlintide Acetate hereunder, Manufacturer will verify the quantity and
identity of such shipment of Pramlintide Acetate according to test methods
approved and provided by Company and shall inspect the Pramlintide Acetate in
accordance with Manufacturer’s incoming material inspection procedures.  If Manufacturer detects any discrepancies in
the Pramlintide Acetate in quantity or in the identity based on the identity
testing performed, Manufacturer shall inform Company immediately upon, but no
later than five (5) Business Days after, having detected such
discrepancies.  Manufacturer shall also
inform Company of any obvious damage to the Pramlintide Acetate or container
received within five (5) Business Days of Manufacturer’s receipt thereof.  Any rejected Pramlintide Acetate shall be
returned at Company’s expense and direction. Company shall make all final
determinations if Materials are suitable for use in Product manufacturing.

4.2          Manufacture of Product. 
Manufacturer will manufacture and store Product at the Facilities in
accordance with the Quality Agreement, the Specifications, applicable
Regulatory Approvals, cGMPs and other Applicable Laws, as then in effect.  Manufacturer shall not rework any Batch of
the Product without Company’ prior written consent, which consent shall not be
unreasonably withheld.  Manufacturer
shall allow an employee of Company (and, with Manufacturer’s prior consent,
other persons) to be present during all manufacturing of the Product. The
Manufacturer shall perform quality control and quality assurance testing to
protocols and procedures agreed in writing between the parties prior to
shipment of Product to the Company. The Manufacturer shall test a portion of
each Batch manufactured for the Company prior to delivering such Batch to the
Company, and shall provide a Certificate of Analysis (i) confirming that the
Manufacturer followed the agreed methods for the testing of such Product, (ii)
containing the quality control and quality assurance test results for such
Batch and (iii) confirming that such Batch has been manufactured in accordance
with the Batch Records and cGMP. The Manufacturer shall notify the Company
immediately of any test failures noted in the manufacture of Product.

4.3          Change in Specifications or
Manufacturing Process.

(a)           Each party shall notify the other in
advance of any proposed changes in Specifications, release testing, stability
testing, packaging, Materials, equipment, facilities, processes or procedures
used to manufacture Product under this Agreement.  No changes in Specifications, release
testing, stability testing, packaging or the Materials, equipment, facilities,
processes or procedures used to manufacture Product under this Agreement,
except changes required by any applicable Regulatory Authority, will be made
unless the parties have agreed to such changes in writing prior to adoption of
such changes. Any such changes to the
Product Specifications, release testing, stability testing, packaging,
Materials, equipment, facilities, processes or procedures used to manufacture
Product shall be handled in accordance with
the procedures established in the Quality Agreement, with costs paid as
provided in Section 4.3(b), (c) or (d), as applicable.

(b)           In the event
Company requests any such changes be made, other than changes described in
Section 4.3(d), Manufacturer shall accommodate Company’s requested changes
to the extent technologically feasible.  If such changes would result in material
change in the cost of manufacture, then in that event the Product Price may be
suitably

 9
 

 CONFIDENTIAL

modified. If such
changes require the purchase of capital equipment, such costs and any related
installation and qualification costs will be to the account of the Company and
such capital equipment shall be owned by the Company.

(c)           In the event
Manufacturer requests any such changes be made, other than changes described in
Section 4.3(d), and such changes would result in a material increase in
Manufacturer’s cost of manufacture, all costs reasonably required in connection
with such changes shall be paid as mutually agreed by the parties.

(d)           In the event
changes are requested by a Regulatory Authority or required to bring either of
the Facilities into compliance with Applicable Laws, or additional changes,
activities, or manufacturing is required to bring the Manufacturing Process
into compliance with Applicable Laws, Specifications or other Product
Requirements, Manufacturer shall accommodate such changes to the extent
technologically feasible, and all costs reasonably required in connection with
such changes, activities, or manufacturing shall be borne by the
Manufacturer.  In such an event the Product Price may be
suitably revised to accommodate such changes.

4.4          Regulatory Matters.

(a)           Manufacturer shall provide to Company such
documentation, data and other information relating to the Facilities, Product, or Manufacturer’s
Manufacturing Processes and procedures for Product as Company may request for
submission to Regulatory Authorities.

(b)           Company shall be responsible for all filings necessary
for Regulatory Approvals.  The parties
agree that Company shall be the sole and exclusive owner of all right, title
and interest in and to all Drug Approval Applications and Regulatory Approvals
related to the Product in the United States and any OUS Country. Manufacturer
shall assist Company in the preparation of all documents necessary to
effectuate Company’s rights in all Drug Approval Applications and Regulatory
Approvals related to the Product and agrees to transfer, effect, confirm,
perfect, record, preserve, protect and enforce all rights, title and interests
transferred hereunder, at the reasonable request and expense of Company.
Manufacturer will use commercially reasonable efforts to assist Company in
obtaining such Regulatory Approvals. For the avoidance of doubt, Company has
sole responsibility for the content of all Drug Approval Applications.  This Agreement automatically terminates if
Amylin terminates development of the Product following final rejection of the
Product by the FDA.

4.5          Compliance with Quality Agreement and
Applicable Laws.  The parties shall comply with the terms
and conditions of the Quality Agreement. Manufacturer shall comply with all
Applicable Laws with respect to activities under this Agreement.   Manufacturer represents and warrants to
Company that it has and will maintain during the Term all establishment
licenses and permits, including without limitation health, safety and
environmental permits, necessary for the conduct of Manufacturer’s activities
under this Agreement.

4.6          Manufacturer Facilities. 
Manufacturer warrants and represents that it has, and will maintain, all
licenses, permits and approvals necessary to fulfill its obligations

 10
 

 CONFIDENTIAL

under this
Agreement.  Manufacturer covenants to
design and operate the facilities it uses to manufacture, package, test, or
store Product to successfully pass inspections conducted by regulatory
authorities. Manufacturer agrees to
maintain appropriate security measures at its facilities no less stringent than
measures that are customary in the pharmaceutical industry.

4.7          QA Audits. Upon written notice of no less than
[***] Business Days for routine audits to Manufacturer, Company shall have the
right to have representatives visit the Facilities
during normal business hours to review Manufacturer’s manufacturing operations,
assess its compliance with cGMPs and quality assurance standards, and discuss
any related issues with Manufacturer’s manufacturing and management
personnel.  Manufacturer shall maintain
the Facilities in accordance with cGMPs. 
Manufacturer’s failure to correct any cGMP deficiency regarding any
aspect of Manufacturer’s manufacture within a reasonable time period after
notice of such deficiency shall be a material breach of this Agreement. Upon
reasonable notice, the Manufacturer will allow employees of the Company access
to the Facility, documentation, and personnel to audit and for observation of
the production process and quality control testing of the Product, disposal of
waste and adherence to cGMP requirements and this Agreement. During such
inspections, employees of the Company (number of persons should be restricted
to not more than [***]) shall have the right to audit any aspect of the
Manufacturers manufacture of Product, and such audit may include, without
limitation, verification of Manufacturers maintenance of drug establishment
registrations with the FDA and other applicable Regulatory Authorities, and
review of conditions and documentation of any aspect of manufacture of Product.

4.8          Regulatory Inspections. Manufacturer agrees to permit the FDA
and other Regulatory Authorities to inspect any aspect of Manufacturer’s
manufacture and testing of the Product including, without limitations, any
pre-approval inspection (“PAI”). Manufacturer shall cooperate with Company, and
with any Regulatory Authority, as necessary to facilitate prompt approvals by
such Regulatory Authority of the Manufacturing Process or testing process for
the Product, including preparation and submission of necessary data relating to
the manufacturing or testing processes, including without limitation any PAI or
subsequent inspection. Manufacturer shall notify Company if either or both of
the Facilities are the subject of an
inspection by any Regulatory Authority or any compliance inspection relating
to, or that could reasonably be expected to, affect the manufacture or storage
of the Product or its production at the Facilities.
Manufacturer shall provide such notification, by telephone and fax, as soon as
Manufacturer becomes aware of the inspection, but not later than two (2)
Business Days from the time Manufacturer becomes aware of the inspection. In
connection with any such inspection, including without limitation a PAI,
Manufacturer shall allow employees or representatives of Company to be present
during the inspection. Manufacturer shall allow Company to participate in the
formulation of any response to regulatory inspections or any other issues
raised by any Regulatory Authority related to Product. Manufacturer will also
simultaneously provide Company with photocopies of any responses provided to
any Regulatory Authority, including, without limitation, responses to any FDA
483 or similar reports. Manufacturer shall keep Company fully informed as to
any Manufacturer communication with any Regulatory Authority related to
Product.

4.9          Investigation of Failed Batch. 
Manufacturer shall investigate, and cooperate fully with Company in
investigating any Batch that fails to meet the Product

***CONFIDENTIAL TREATMENT REQUESTED

 11
 

 CONFIDENTIAL

Requirements or
that incurs a significant deviation from expected Manufacturing Process.  Manufacturer shall keep Company informed of
the status of any investigation and, upon completion of the investigation,
shall provide Company with a final written report describing the cause of the
failure or deviation and summarizing the results of the investigation.

4.10        Documentation. Manufacturer shall keep complete,
accurate and authentic accounts, notes, data and records of the work performed
under this Agreement, including, without limitation, master production and
control records and Product complaint files, in accordance with Applicable
Laws.  In addition, Manufacturer shall
retain and store samples of each Batch only as required by Applicable Laws.  The sample size shall be twice the size necessary
to conduct quality control testing. Manufacturer shall retain such records and
samples for the periods required by Applicable Laws. Upon Company’s request,
Manufacturer shall make available copies of such records and portions of the
samples to Company.  After such time
period, Manufacturer shall notify Company prior to destroying such records and
samples and, at Company’s request and expense, shall provide copies of such
records and any remaining samples to Company. 
The Manufacturer shall not be obliged to retain any samples thereafter
and after due intimation to the Company, the Manufacturer shall destroy the
remaining samples.

4.11        Complaints and Adverse Reaction. 
Each party shall promptly advise the other of any complaints, adverse
reaction reports, safety issues or toxicity issues relating to Product of which
it becomes aware, which may be the result of, or have an effect on, the
manufacturing or packaging operations performed by Manufacturer. Company shall
be responsible for all reporting of such information to Regulatory Authorities.

4.12        Labeling; Trademark. 
Manufacturer shall affix labeling to the Product as directed by
Company.  Nothing in this Agreement gives
Manufacturer the right to use any trademark or trade name of Company except as
specified in writing by Company. 
Manufacturer shall not affix any label, stamp or other mark identifying
Manufacturer as the source of the Product except as instructed in writing by
Company or as may be required by Applicable Laws.

5.             Delivery
and Acceptance.

5.1          Delivery. 
Unless otherwise agreed by the parties in writing, all shipments shall
be shipped FCA (Incoterms 2000) the Facilities
by air freight to the destination specified by Company in the applicable
purchase order. Manufacturer shall make each shipment of the Product in the
quantity, cartridge size and on the shipment date specified for it on Company’s
purchase order, via the mode(s) of transportation and to the party and
destination specified on such purchase order. Manufacturer will package and ship
the Product in accordance with Manufacturer’s customary practices for
pharmaceutical products, unless otherwise specified by Company.  Manufacturer shall deliver Product ordered by
Company on the scheduled delivery dates set forth in the relevant purchase
orders, subject to the provisions of Section 2.4.  If Company is not ready to accept shipment of
Product on the date Manufacturer is prepared to ship Product, then Manufacturer
shall store Product in a manner consistent with customary practices for pharmaceutical
products and Company shall pay Manufacturer a commercially reasonable storage
fee.  Company and Manufacturer agree to
negotiate the amount of such storage fee in good faith.

 

 12

CONFIDENTIAL

5.2          Title. Title to all Pramlintide Acetate shall at all times
remain in Company.  Title to all
Materials other than Pramlintide Acetate, work in progress to produce Product,
and all completed Product (except Pramlintide Acetate contained therein) shall
remain with Manufacturer until delivery of such Product to carrier designated
by the Company.  Notwithstanding the
foregoing, and regardless of whether delivery of Product to Company has
occurred under Section 5.1, Manufacturer shall bear all risk of loss with
respect to, and shall insure, all Product until transfer by Manufacturer to a
carrier for shipment as directed by Company in the applicable purchase order.

5.3          Acceptance and Rejection.

(a)           Concurrent with the delivery of any Batch, Manufacturer
shall provide Company with all documentation required to be provided to Company
under the Quality Agreement, including, without limitation, a Certificate of
Analysis and Certificate of Compliance for such Batch.  Company may reject delivery of any Batch that
does not conform with the Product Requirements. 
Any such notice of rejection shall be in writing and shall indicate the
reasons for such rejection.

(b)           In order to reject delivery of a Batch, Company must
give written notice to Manufacturer of Company’ rejection of any delivery
within [***] days after receipt of such delivery.  If no such notice of rejection is received,
Company shall be deemed to have accepted such delivery of the Batch [***] days
after delivery of the Batch, except in the case of Hidden Defects.  If Company discovers in a Batch a Hidden
Defect, such as a Contaminant, at any time after acceptance of such Batch,
Company shall notify Manufacturer within [***] days of discovering such Hidden
Defect and shall have the right to reject the Batch under the procedures
regarding rejection set forth in Section 5.3(c), (d) and (e), as
applicable.

(c)           After notice of rejection is given, Company shall
cooperate with Manufacturer in determining whether rejection is justified.  Manufacturer shall notify Company as promptly
as reasonably possible (and in any event within [***] days after notice of
rejection from Company) if Manufacturer does not agree that such rejection is
justified.  If no such notice from Manufacturer
is received, Manufacturer shall be deemed to agree that such rejection is
justified. Should Company reject any Batch and Manufacturer agree that such
rejection is justified or if applicable, a third party determines such
rejection is justified pursuant to the provisions of Section 5.3(d),
Manufacturer shall (i) reimburse amounts paid to Manufacturer by Company
pursuant to Section 3.1. and (ii) shall manufacture and supply the next Batch
of Product ordered by Company at no cost to Company.  Compliance with the provisions of this Section 5.3(c)
and 5.3(d) and 5.3(e) shall be Manufacturer’s sole liability to Company where
Company rejects a Batch of and either Manufacturer agrees, or a third party
determines under Section 5.3(d), that such rejection is justified, subject
only to Section 10.4.

(d)           If Manufacturer in good faith disagrees with Company’s
determination that rejection of a Batch is justified, certain of the Product in
such Batch shall be submitted to a mutually acceptable third party laboratory
or expert. Such third party shall determine whether such Product meets the
Specifications, and the parties agree that such third party’s determination
shall be final and determinative. The party against whom the third party
tester/expert rules shall bear all costs of the third party testing.  Whether or not Manufacturer 

***CONFIDENTIAL TREATMENT REQUESTED

 13
 

CONFIDENTIAL

accepts Company’s basis
for rejection, promptly on receipt of a notice of rejection of a Batch,
Manufacturer shall replace such rejected Batch within [***] days.  If the third party tester/expert rules that
the Batch meets Specifications and those warranties pursuant to Sections 8.3
(a), (b), (c), (d) and (e), Company shall purchase that Batch at the
agreed-upon price, irrespective of whether Manufacturer has already replaced
it. All replacement Product shall be invoiced as well and Company shall pay for
such Product as otherwise provided under the terms of this Agreement. If third
party tester/expert agrees that rejection was justified then Manufacturer shall
(i) reimburse Company amounts paid by Company pursuant to Section 3.1 and (ii)
shall manufacture and supply the next Batch of Product ordered by Company at no
cost to Company. Compliance with the provisions of this Section 5.3(d) and
payment of the costs in Section 5.3(e) shall be Manufacturer’s sole only
liability to Company where Company rejects a Batch of and either Manufacturer
agrees, or a third party determines under Section 5.3(d), that such
rejection is justified, subject only to Section 10.4.  Manufacturer shall have no further liability
to the Company in respect of such Batch except to what is stated herein.

(e)           Company may not destroy any Batch until [***] days
after rejection unless, prior to that date, Company receives written
notification from Manufacturer that Manufacturer does not agree that such
rejection is justified or that Manufacturer requests return of such rejected
Batch.  Company shall destroy such
rejected Batch promptly at Manufacturer’s cost and provide Manufacturer with
certification of such destruction. 
Company shall, upon receipt of Manufacturer’s request for return,
promptly return such Batch to Manufacturer, at Manufacturer’s cost.

5.4          Recalls and Similar Actions.

(a)           If
there is a recall, withdrawal or field correction with respect to, or any
governmental seizure of, Product (“Recall Action”), which Recall Action is
considered by the Company to be due in part to a failure of the Manufacturer to
comply with its warranties stated in Section 8.3 of this Agreement then Company
will notify Manufacturer promptly of the details regarding such Recall Action,
including providing copies of all relevant documentation concerning such Recall
Action. Manufacturer will assist Company in investigating any such Recall
Action, if Company so requests, and all regulatory contacts that are made and
all activities concerning such Recall Action will be initiated and coordinated
by Company with Manufacturer’s involvement and assistance, as reasonably
requested by Company.

(b)           If
any Recall Action occurs which is considered by the Company to be due in part
to a failure of the Manufacturer to comply with its warranties stated in
Section 8.3 of this Agreement and Manufacturer agrees with said consideration
then Manufacturer shall, to the extent and only to the extent of its relative
responsibility, bear the cost and expense of any such Recall Action. Therefore,
if both Manufacturer and Company contribute to the cause of such a Recall
Action, the cost and expense thereof will be shared in proportion to each party’s
contribution to the problem.

(c)           If
any Recall Action occurs which is considered by the Company to be due in part
to a failure of the Manufacturer to comply with its warranties stated in
Section 8.3 of this Agreement and Manufacturer disagrees with said consideration
then the parties shall refer to a mutually acceptable third party expert. Such
third party shall determine if Manufacturer 

***CONFIDENTIAL TREATMENT REQUESTED

 14
 

CONFIDENTIAL

has complied with
its warranties stated in Section 8.3. If such a determination is made
Manufacturer shall have no liability towards the cost and expense of the Recall
Action. If the third party determines Manufacturer has not complied with its
warranties stated in Section 8.3 Manufacturer shall, to the extent and only to
the extent of its relative responsibility, bear the cost and expense of any
such Recall Action.

6.             Protection
of Confidential Information.

6.1          Confidentiality. 
During the Term and for a period of ten (10) years thereafter, each
party (the “Receiving Party”)
agrees with respect to any Confidential Information of the other party (the “Disclosing Party”):

(a)           To use such Confidential Information only for the
purposes set forth in this Agreement;

(b)           To receive, maintain and hold the Confidential
Information in confidence;

(c)           Not to disclose, or authorize or permit the disclosure
of, any Confidential Information to any third party without the prior written
consent of the Disclosing Party; and

(d)           Except as needed to fulfill its obligations hereunder,
to return any Confidential Information to the Disclosing Party at the request
of the Disclosing Party and to retain no copies or reproductions thereof.

6.2          Limitations. 
The Receiving Party shall not be obligated to treat as Confidential
Information, information that the Receiving Party can show by competent written
evidence:

(a)           was already known to the Receiving Party without any
obligations of confidentiality prior to receipt from the Disclosing Party;

(b)           was generally available to the public or otherwise
part of the public domain at the time of its disclosure to the Receiving Party;

(c)           became generally available to the public or otherwise
part of the public domain after its disclosure, other than through any act or
omission of the Receiving Party in breach of any obligation of confidentiality;

(d)           was disclosed to the Receiving Party, other than under
an obligation of confidentiality, by a third party who had no obligation not to
disclose such information to others; or

(e)           was independently discovered or developed by the
Receiving Party without the use of the Disclosing Party’s Confidential
Information.

 15
 

CONFIDENTIAL

6.3          Authorized Disclosure. 
Notwithstanding Section 6.1, the Receiving Party may disclose
Confidential Information, without violating the obligations of this Agreement,
to the extent the disclosure is required by Applicable Laws or a valid order of
a court or other governmental body having jurisdiction; provided that the
Receiving Party gives reasonable prior written notice to the Disclosing Party
of such required disclosure and makes a reasonable effort to obtain, or to
assist the Disclosing Party in obtaining, a protective order preventing or
limiting the disclosure and/or requiring that the Confidential Information so
disclosed be used only for the purposes for which the law or regulation
requires, or for which the order was issued. 
Further, the Receiving Party may disclose Confidential Information of
the Disclosing Party solely to the extent (a) such disclosure is
reasonably necessary in advising investors and the investment community of the
results of the research, development or commercialization activities hereunder
(subject to the prior written consent of the Disclosing Party, which consent
will not be unreasonably withheld), or (b) such disclosure is made to
Affiliates, employees, consultants or agents to other third parties in
connection with due diligence by such Third Parties, or to potential third
party investors in confidential financing documents, provided, in each case,
that any such Affiliate, employee, consultant, agent or third party is subject
to confidentiality and non-use obligations with respect to such information.

6.4          Use of Name/Publicity. 
Neither party shall use the other party’s name in connection with any
publication or promotion without the other party’s written consent, except as
required by federal, state or local laws, rules and regulations.  Manufacturer shall not disclose the specific
content or terms of this Agreement without the prior written consent of Company.

7.             Intellectual
Property Rights.

7.1          Company Inventions. 
All right, title and interest in and to any intellectual property rights
in Pramlintide Acetate and Product shall at all times be and remain the sole
and exclusive property of Company. 
Company shall solely own, and shall alone have the right to apply for
patents, patent rights and inventor’s certificates, on any invention, method,
process, discovery or know-how (whether or not patentable) which is conceived
solely by Company, its consultants or agents (other than Manufacturer) in the
performance of this Agreement (“Company Inventions”).

7.2          Manufacturer Inventions. 
Manufacturer shall solely own, and shall alone have the right to apply
for patents, patent rights and inventor’s certificates, on any invention, method,
process, discovery or know-how (whether or not patentable) which is conceived
solely by Manufacturer, its consultants or agents in the performance of this
Agreement (“Manufacturer Inventions”).

7.3          Joint Inventions. 
Any invention, method, process, discovery or know-how (whether or not
patentable) not conceived solely by either Company and Manufacturer or their
respective consultants or agents during the performance of this Agreement (“Joint Inventions”) shall be jointly
owned by Company and Manufacturer.  The
law of joint ownership of patents of the United States shall apply to joint
ownership of any Joint Inventions inside and outside of the United States.
Where appropriate, the parties may engage outside counsel agreeable to both
parties (the costs of which shall be borne equally by the parties) to represent

 16
 

CONFIDENTIAL

them jointly in the
prosecution of patent applications and the maintenance of patents with respect
to Joint Inventions.

7.4          Prosecution. 
Should either party not wish to file, prosecute, maintain or issue a
patent application or maintain a patent covering such party’s interest in a
Joint Invention, then such party  (the “Granting Party”) shall, at the
other party’s election, grant to the other party (i) a perpetual, irrevocable,
exclusive (even as to the Granting Party and its Affiliates), worldwide, fully
paid-up royalty-free license under the Granting Party’s interest in the Joint
Invention, with the right to grant sublicenses, to develop, make, have made,
use, import, offer to sell, have sold and sell products, and (ii) any necessary
authority to file, prosecute, maintain and issue such a patent application or
maintain such a patent, all at the expense of the party requesting that such
filing be made or action be taken.

7.5          Assistance. 
Upon request, Company and Manufacturer shall each provide the other with
reasonable assistance in obtaining patents and, if necessary, enforcing patent
rights in Manufacturer Inventions, Company Inventions or Joint Inventions, as
applicable.  To that end, each party
agrees to assist the other in executing, verifying and delivering such
documents and performing such acts as may be reasonably requested by the other
party in applying for, obtaining, perfecting, evidencing, sustaining or
enforcing the other party’s rights in Manufacturer Inventions, Company
Inventions or Joint Inventions, as applicable. 
The party requesting such assistance shall reimburse the assisting party
for all reasonable out-of-pocket expenses incurred and provide reasonable
compensation for time spent in providing such assistance, except in the case of
any patent covered by a Joint Invention, in which case no compensation shall be
provided and all expenses shall be [***] by the parties (i.e.,
[***]% paid by Company and [***]% paid by Manufacturer).

7.6          Infringement. 
Each party shall promptly notify the other of any potential alleged or
threatened infringement of patents claiming any Company Invention, Manufacturer
Invention or Joint Invention, or of any allegation by a third party of which it
becomes aware that the activity of Company or Manufacturer pursuant to this
Agreement infringes a third party’s patent rights.

7.7          Manufacturing Process License;
Technology Transfer.  Manufacturer hereby grants Company a
perpetual, irrevocable, exclusive, worldwide, royalty-free, fully paid-up
license, with the right to sublicense, to all of Manufacturer’s rights in and
to the Manufacturing Process, including any Manufacturer Inventions, to
use,  import, make, have made, offer to
sell, have sold and sell Product or any other product containing Pramlintide
Acetate; provided, however, if Company or any sublicensee
of Company or any successor business or assignee wishes Manufacturer to assist
in the transfer of the Manufacturing Process to another manufacturer,
Manufacturer shall have the right to charge a commercially reasonable fee based
on FTE rates for providing training and other assistance requested by such
party in connection with such technology transfer.  Notwithstanding the foregoing, if any such
transfer of the Manufacturing Process to a third party results in a transfer of
the Manufacturer’s Technology, the parties agree to meet for the purpose of
determining the appropriate royalty amount to be paid to the Manufacturer.

***CONFIDENTIAL
TREATMENT REQUESTED

 17
 

CONFIDENTIAL

8.             Representations
and Warranties.

8.1          No Inconsistent Obligations. 
Each party represents and warrants that the terms of the Agreement are
not inconsistent with its other contractual arrangements or obligations.

8.2          Due Authorization. 
Each party represents and warrants that (a) it has full power and
authority to enter into this Agreement, (b) this Agreement has been duly
authorized by it, and (c) this Agreement is binding upon it.

8.3          Product Warranties. 
Manufacturer represents and warrants that Product delivered hereunder
will:

(a)           be manufactured by Manufacturer in accordance with
cGMPs and relevant Regulatory Approvals;

(b)           conform to the Specifications at the time of delivery;

(c)           not contain any Contaminant or be adulterated within
the meaning of the FDCA or any other Applicable Law in which the definitions of
adulteration are substantially the same as those contained in the FDCA, as such
laws are constituted and effective at the time of delivery;

(d)           not be an article which may not, under the provisions
of Sections 404, 505 of 512 of the FDCA, be introduced into interstate
commerce; and

(e)           be free and clear of any lien or encumbrance.

Company’s remedies and Manufacturer’s liability with
respect to the warranties set forth in this Section 8.3 are set forth in
Section 5.3(d) above.

8.4          The Company represents, warrants and agrees that:

a)             The manufacture of
Product as contemplated herein, will not, to the Company’s knowledge, infringe
any existing patents or any other proprietary rights of third parties, and as
of the date hereof Company has not received any notice of any claimed
infringement (including without limitation patent infringement) in connection
with Pramlintide Acetate.

b)            The Company, to the
Company’s knowledge, and its employees have never been debarred or convicted of
a crime for which a person can be debarred, under subsection (a) or (b) of 21
U.S.C. § 335a, as amended, and Company agrees that it does not now and does not
intend in the future to use in any capacity the services of any person debarred
under subsection (a) or (b) of 21 U.S.C. §335a, as amended.  If, during the term of this Agreement,
Company or any other person performing under this Agreement becomes debarred or
disqualified, or receives notice of an action or threat of an action with
respect to debarment or disqualification, Company shall promptly notify
Manufacturer.

 18
 

CONFIDENTIAL

8.5          No Debarred or Disqualified Persons. Manufacturer represents and warrants
that it is not currently and it shall not employ, contract with, or retain any
person directly or indirectly to perform any services under this Agreement if
such a person (a) is under investigation by the FDA for debarment or is
presently debarred by the FDA pursuant to 21 U.S.C. § 335a or its successor
provisions or any regulations promulgated thereunder, (b) has a
disqualification hearing pending or has been disqualified by the FDA pursuant
to 21 CFR § 312.70 or its successor provisions or (c) is subject to similar
investigation or disqualification pursuant to any other relevant regulatory
authority.  In addition, Manufacturer
represents and warrants that it has not engaged in any conduct or activity
which could lead to any of the above-mentioned disqualification or debarment
actions.  If, during the Term,
Manufacturer or any person employed or retained by it to perform any services
under this Agreement (i) comes under investigation by the FDA for a
debarment action or disqualification, (ii) is debarred or disqualified, or
(iii) engages in any conduct or activity that could lead to any of the
above-mentioned disqualification or debarment actions, Manufacturer shall
immediately notify Company of same.

8.6          Disclaimer. 
Except as set forth above, NEITHER PARTY MAKES ANY REPRESENTATIONS OR
WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, AND EXPRESSLY DISCLAIMS ALL
IMPLIED WARRANTIES OF TITLE, NON-INFRINGMENT, MERCHANTIBILITY, AND FITNESS FOR
A PARTICULAR PURPOSE.

8.7          Limitation of Liability. 
NEITHER PARTY SHALL BE ENTITLED TO RECOVER FROM THE OTHER PARTY ANY
SPECIAL, INCIDENTAL, CONSEQUENTIAL OR PUNITIVE DAMAGES IN CONNECTION WITH THIS
AGREEMENT OR ANY LICENSE GRANTED HEREUNDER. 
This Section 8.7 shall not be construed to limit either party’s
indemnification obligations under Section 10 or to limit remedies
available for breach of confidentiality and non-use obligations or for
infringement or misappropriation of intellectual property rights.

9.             Term
and Termination.

9.1          Term.  The term of
this Agreement shall commence on the Effective Date and, unless terminated
earlier as provided herein, shall continue until the expiration of the Fifth
Period, subject to renewal by mutual written agreement of the parties (the “Term”).

9.2          Termination by Either Party.  A
party may terminate this Agreement:

(a)           for material breach of this Agreement by the other
party upon sixty (60) days’ written notice specifying the nature of the breach,
if such breach has not been cured within such sixty (60) day period; provided,
this Agreement may be terminated immediately if the breach is incapable of
remedy or has not been corrected by the breaching party within sixty (60) days
after written notice; or

(b)           immediately upon written notice to the
other party, if the other party makes a general
assignment for the benefit of creditors, files an insolvency petition in
bankruptcy, petitions for or acquiesces in the appointment of any receiver,
trustee or similar 

 19
 

CONFIDENTIAL

officer
to liquidate or conserve its business or any substantial part of its assets,
commences under the laws of any jurisdiction any proceeding involving its
insolvency, bankruptcy, reorganization (other than a reorganization without
insolvency), dissolution, liquidation or any other similar proceeding for the
release of financially distressed debtors or becomes a party to any proceeding
or action of the type described above and such proceeding or action remains
undismissed or unstayed for a period of more than sixty (60) days.

9.3          Termination by Company. 
Company may terminate this Agreement:

(a)           at any time after the expiration of the Fifth Period
upon one (1) year’s prior written notice to Manufacturer;

(b)           at any time prior to the Launch Date in the event that Company makes a good faith
determination that it will not continue with the commercialization of Product,
upon at least sixty (60) days prior written notice to Manufacturer, and
such termination shall be effective at the end of such sixty (60) day period;
provided that Company shall remain obligated to pay for Product ordered under
any purchase orders issued by Company to Manufacturer prior to such effective
termination date.

(c) immediately upon written notice to
Manufacturer if Manufacturer (i)  has its
manufacturing authorizations for the Product suspended or withheld (ii) in the
case of a PAI, fails to pass an inspection by a Regulatory Authority (iii) in
the case of a regulatory inspection by a Regulatory Authority fails to pass an
inspection and has not taken, within one hundred (100) Business Days, such
action as is necessary to correct the items cited by the Regulatory Authority.

9.4          Automatic
Termination. In the event Company notifies Manufacturer that
it has terminated development of Pramlintide Acetate following the receipt by
Company of notice of final rejection by the FDA for marketing authorization for
commercial sale and distribution of Product in the United States, then this
Agreement shall automatically terminate.

9.5           Survival Upon Termination. Expiration or termination of this Agreement will not
relieve the parties of any obligation accruing prior to such expiration or
termination. Sections 1, 3.8, 4.7, 4.10, 6, 7, 8.3, 8.5, 8.7, 9.5, 9.6,
10, 11 and 12 will survive termination of this Agreement.

9.6          Remedies.  In the event
of any breach of any provision of this Agreement, in addition to the termination
rights set forth herein, each party shall have all other rights and remedies at
law or equity to enforce this Agreement.

10.          Indemnification.

10.1        By Company. 
Company agrees to indemnify, defend and hold harmless Manufacturer and
its Affiliates and their respective officers, employees and agents (“Manufacturer Indemnitees”) from any
loss, expense (including reasonable legal counsel fees and expenses), cost,
liability or damages (“Losses”)
incurred by any Manufacturer Indemnitee as 

 20
 

CONFIDENTIAL

a result of any claim,
demand, action or other proceeding by any third party (“Claim”)
arising out of or related to (a) Company’s breach of any representation or
warranty made by Company in this Agreement or (b) the handling,
possession, storage or use of Product by or on behalf of Company following
delivery by Manufacturer to Company, except to the extent Manufacturer is
obligated to indemnify Company with respect to such Losses under
Section 10.2 or the Losses are based on the negligence or willful misconduct
of any Manufacturer Indemnitee. 
Manufacturer Indemnitees shall promptly and in any event within thirty
(30) days notify Company of any known Claim which is the subject of Losses.  Manufacturer Indemnitees shall fully
cooperate with Company in the defense or settlement of any claim of Losses
under this Section 10.1; provided,
however, that no
Manufacturer Indemnitee shall be required to admit fault or responsibility in
connection with any settlement. 
Manufacturer Indemnitees shall have the right to select and to obtain
representation by separate legal counsel at its own expense.

10.2        By Manufacturer. 
Manufacturer shall indemnify, defend and hold harmless Company and its
Affiliates and their respective officers, employees and agents (“Company Indemnitees”) from and
against any and all Losses to which any Company Indemnitee may become subject
as a result of any Claim arising out of or related to (a) Manufacturer’s
breach of any representation or warranty made by Manufacturer in this Agreement
or (b) the handling, possession, storage or use of Pramlintide Acetate or
Product by or on behalf of Manufacturer prior to delivery of Product by
Manufacturer to Company, except to the extent Company is obligated to indemnify
Manufacturer with respect to such Losses under Section 10.1 or the Losses
are based on the negligence or willful misconduct of any Company
Indemnitee.  Company Indemnitee shall
promptly and in any event within thirty (30) days notify Manufacturer of any
known Claim which is the subject of Losses. 
Company Indemnitees shall fully cooperate with Manufacturer in the
defense or settlement of any claim of Losses under this Section 10.2; provided, however, that no Company Indemnitee
shall be required to admit fault or responsibility in connection with any
settlement.  Company Indemnitees shall
have the right to select and to obtain representation by separate legal counsel
at Company’s own expense.

10.3        Loss of Pramlintide Acetate Drug
Substance.  If any Pramlintide Acetate Drug Substance is
destroyed, damaged or lost while in Manufacturer’s custody, control or storage
prior to its use in the manufacture of the Product, Manufacturer’s liabilities
shall be determined at a rate of [***] US dollars ($[***]) per gram] of
Pramlintide Acetate Drug Substance and limited to a maximum of [***] US dollars
($[***]) for each individual incidence of loss. 
For the avoidance of doubt Manufacturer shall not be liable for loss of
Pramlintide Acetate Drug Substance if peptide content has deteriorated and
Manufacturer has complied fully with the storage requirements for Pramlintide
Acetate Drug Substance as specified by Company.

10.4        Restriction on Limitation of Liability. 
Nothing in this Agreement shall limit a party’s liability in respect of
death or personal injury caused by the negligence of that party or its
liability in respect of fraudulent misrepresentation.

11.          Dispute
Resolution

11.1        Discussions Between the Parties. 
If any claim, dispute, or controversy of whatever nature arising out of
or relating to this Agreement, including, without limitation, any action or
claim based on tort, contract, or statute (including any claims of breach or
violation of 

***CONFIDENTIAL
TREATMENT REQUESTED

 21
 

 

CONFIDENTIAL

statutory or common law
protections from discrimination, harassment and hostile working environment),
or concerning the interpretation, effect, termination, validity, performance
and/or breach of this Agreement (“Disputed Claim”),
arises between the parties and the parties cannot resolve the dispute within
thirty (30) days of a written request by either party to the other party, the
parties agree to hold a meeting, attended by the an executive officer or their
equivalent of Company and Manufacturer, to attempt in good faith to negotiate a
resolution of the dispute prior to pursuing other available remedies.  If, within sixty (60) days after such written
request, the parties have not succeeded in negotiating a resolution of the
dispute, such dispute shall be resolved by final and binding arbitration in
accordance with Section 11.2.

11.2        Arbitration.

(a)           Arbitration of Disputed Claims between the parties
under this Section 11.2 shall be conducted in accordance the Rules of the
International Chamber of Commerce, Court of Arbitration, Paris (the “ICC”), except to the extent the
provisions of this Section 11.2 conflict with such Rules, in which case the
provisions of this Section 11.2 shall prevail.

(b)           The arbitration shall be conducted by three (3)
arbitrators who shall be knowledgeable in the subject matter which is at issue
in the dispute and have no current or past affiliation with either party or
their respective Affiliates.  Each party
shall select one of the arbitrators within thirty (30) days after notice of
arbitration under this Section 11.2, and the third arbitrator, who shall act as
the Chair of the arbitration, shall be appointed by the ICC.

(c)           The arbitrators shall determine what discovery will be
permitted, consistent with the goal of limiting the cost and time that the
parties must expend for discovery; provided that the arbitrators shall permit
such discovery as the arbitrators deem necessary to permit an equitable
resolution of the dispute.  The
arbitrators shall have sole discretion with regard to the admissibility of any
evidence.

(d)           No later than ninety (90) days after the arbitrators
are selected (or such other period of time as agreed to by the parties in
writing), the arbitrators will hold the arbitration hearing to resolve each of
the issues identified by the parties. 
The arbitrators may conduct additional arbitration hearings if the
arbitrators deem appropriate; provided that all arbitration hearings will be
completed by no later than one hundred twenty (120) days after the arbitrators
are selected (or such other period of time as agreed to by the parties in
writing).  Each party will have the right
to be represented by counsel at any such arbitration hearing.  The arbitration hearings shall be held in
London, England.

(e)           The arbitration will be confidential and the
arbitrators will issue appropriate protective orders to safeguard each party’s
Confidential Information.  Except as
required by law, no party will make (or instruct the arbitrators to make) any
public announcement with respect to the proceedings or decision of the
arbitrators without the prior written consent of the other party.  The existence of any Disputed Claim, and the
award of the arbitrators, will be kept in confidence by the parties and the
arbitrators, except as required in connection with the enforcement of such
award or as otherwise required by applicable law.

 

 22

 CONFIDENTIAL

(f)            The arbitrators shall, within thirty (30) days after
the conclusion of the arbitration hearings, issue a written award and statement
of decision describing the essential findings and conclusions on which the
award is based, including the calculation of any damages awarded.  The arbitrators shall be authorized to award
compensatory damages, but shall NOT be authorized to (i) award non-economic
damages, such as for emotional distress, pain and suffering or loss of consortium,
(ii) award punitive damages, or (iii) reform, modify or materially change this
Agreement or any other agreements contemplated hereunder; provided, however, that the damage limitations
described in subsections (i) and (ii) of this sentence will not apply if such
damages are statutorily imposed.  The
arbitrators also shall be authorized to grant any temporary, preliminary or
permanent equitable remedy or relief they deem just and equitable and within
the scope of this Agreement, including, without limitation, an injunction or
order for specific performance. The decision of the arbitrators shall be final
and binding upon the parties.  Judgment
on the award rendered by the arbitrators may be entered in any court having
competent jurisdiction thereof.  Nothing
herein shall limit or restrict a party’s ability to seek injunctive or other
equitable relief in the event of a breach or anticipated breach of Section 6.

(g)           Each party has the right before or during the
arbitration to seek and obtain from the appropriate court provisional remedies,
such as attachment, preliminary injunction or replevin, to avoid irreparable
harm, maintain the status quo, or preserve the subject matter of the
arbitration.  This Section 11.2 shall not
apply to any dispute, controversy or claim that concerns (i) the validity or
infringement of a patent, trademark or copyright; or (ii) any antitrust,
anti-monopoly or competition law or regulation, whether or not statutory.

11.3        Costs and Awards. 
Each party shall bear its own attorneys’ fees, costs, and disbursements
arising out of the arbitration, and shall pay an equal share of the fees and
costs of the arbitrators; provided,
however, that the
arbitrators shall be authorized to determine whether a party is the prevailing
party, and if so, to award to that prevailing party reimbursement for its
reasonable attorneys’ fees, costs and disbursements (including, for example,
expert witness fees and expenses, photocopy charges, travel expenses, etc.),
and/or the fees and costs of the arbitrator. 
Absent the filing of an application to correct or vacate the arbitration
award under California Code of Civil Procedure Sections 1285 through 1288.8,
each party shall fully perform and satisfy the arbitration award within fifteen
(15) days of the service of the award.

11.4        Waiver and Acknowledgment. 
By agreeing to this binding arbitration provision, the parties
understand that they are waiving certain rights and protections which may
otherwise be available if a Disputed Claim between the parties were determined
by litigation in court, including, without limitation, the right to seek or
obtain certain types of damages precluded by this provision, the right to a
jury trial, certain rights of appeal, and a right to invoke formal rules of
procedure and evidence.

12.          Miscellaneous.

12.1        Exclusive Facility Utilization Fee.    
Company agrees to pay Manufacturer an exclusive utilization fee upon
receipt of invoice from Manufacturer  of
[***] in lieu of its investments made during the construction of the
manufacturing facility for the exclusive manufacture of the Product pursuant to
that certain Manufacturing Agreement dated April 28, 1999 and the Commercial
Supply Agreement dated 7th October 2004 for the supply of

***CONFIDENTIAL
TREATMENT REQUESTED

 23
 

 CONFIDENTIAL

Exenatide
Cartridges entered into between the parties. If Manufacturer uses said
manufacturing facility for itself or for a third party, then Manufacturer will
provide a credit to Company of [***] per unit of such product. Such credit will
be applied to the first [***] units of product manufactured for the
Manufacturer or a third party.  Further,
Manufacturer shall notify the Company prior to using said manufacturing
facility for purposes of manufacturing cartridges for transfer into
Manufacturer’s inventory or for sale to a third party. On or about each
anniversary date of Manufacturer’s commencing use of the manufacturing facility
for producing units for inventory or third party sales, Manufacturer shall
provide Company written notification of the total number of such units of
cartridges transferred into inventory or sold during the preceding year.  Company shall have the right to conduct an
annual audit of all such cartridges transferred into inventory or sold to third
parties.  Promptly following each such
audit, Company shall invoice Manufacturer for all such cartridges transferred
into inventory or sold to a third party during the preceding year.  Payment shall be due on such invoices not
later than thirty (30) days following receipt thereof.

12.2        No Implied Licenses. 
No right or license is granted under this Agreement by either party to
the other, either expressly or by implication, except those specifically set
forth herein.

12.3        Non-Solicitation.

(a)           Manufacturer shall not, during the Term, employ or
engage or offer to employ or engage any person who during the [***] months
prior to the commencement of such employment or engagement was employed by
Company.

(b)           Company shall not, during the Term, employ or engage
or offer to employ or engage any person who during the [***] months prior to
the commencement of such employment or engagement was employed by Manufacturer
as a [***] (Grade [***] or higher) [***] employee or a [***] employee

(c)           Notwithstanding the foregoing, nothing in this
Agreement shall prohibit (i) the general advertisement of employment positions
by a party in any trade publication or other publication of general
circulation, (ii) the employment of any current employee of Company by
Manufacturer if such person initiates contact with Manufacturer without any
prior solicitation by Manufacturer or on Manufacturer’s behalf, other than as
permitted in clause (i) hereof, or (iii) the employment of any current employee
of Manufacturer by Company if such person initiates contact with Company
without any prior solicitation by Company or on Company’s behalf, other than as
permitted in clause (i) hereof.

12.4        Independent Contractor Relationship. 
Manufacturer’s relationship with Company will be that of an independent
contractor and nothing in this Agreement should be construed to create a
partnership, joint venture, or employer-employee relationship.  Manufacturer is not an agent of Company and
is not authorized to make any representation, contract, or commitment on behalf
of the Company.  Manufacturer will be
solely responsible for all tax returns and payments required to be filed with
or made to any federal, state or local tax authority with respect to
Manufacturer’s performance of services and receipt of fees under this
Agreement.  Manufacturer agrees to accept
exclusive liability for complying with all applicable

***CONFIDENTIAL
TREATMENT REQUESTED

 24
 

 CONFIDENTIAL

state and federal
laws governing self-employed individuals, including obligations such as payment
of taxes, social security, disability and other contributions based on fees
paid to Manufacturer, its agents or employees under this Agreement.  Manufacturer hereby agrees to indemnify and
defend Company against any and all such taxes or contributions, including
penalties and interest.

12.5        Entire Agreement; Amendment. 
This Agreement, together with all exhibits attached hereto and hereby
incorporated herein, constitutes the final, complete and exclusive agreement of
the parties with respect to the subject matter hereof and supersedes and
terminates all prior understandings and agreements relating to its subject
matter, including, without limitation, that certain Manufacturing Agreement
dated April 28, 1999 entered into between the parties.  This Agreement may not be changed, modified,
amended or supplemented except by a written instrument signed by both parties.

12.6        Severability. 
If any provision of this Agreement should be held invalid or
unenforceable, the remaining provisions shall be unaffected and shall remain in
full force and effect, to the extent consistent with the intent of the parties
as evidenced by this Agreement as a whole.

12.7        Assignment; Delegation. 
This Agreement shall inure to the benefit of and be binding upon the
successors and assigns of the parties hereto; provided, however,
that neither Company nor Manufacturer shall transfer or assign this Agreement
without the prior written consent of the other party.  However, Company may assign this Agreement
and its rights and obligations hereunder without such consent to a
Collaboration Partner (as defined below) or in connection with the transfer or
sale of all or substantially all of its assets relating to Pramlintide Acetate
or in the event of Company’s merger or consolidation or change in control of
similar transaction.  Manufacturer may
not subcontract or otherwise delegate its obligations under this Agreement
without Company’ prior written consent.

12.8        Governing Law. 
This Agreement shall be governed by the laws of the State of Delaware,
excluding its conflict of laws principles.

12.9        Headings.  Section
headings are for convenience of reference only and shall not be considered in
the interpretation of this Agreement.

12.10      Days.  Unless
otherwise specified herein, references to a number of days shall reference
calendar days.

12.11      Force Majeure. 
Neither party to this Agreement shall be deemed to be in breach of this
Agreement or otherwise liable to the other party in any manner whatsoever for
any failure or delay in performing its obligations under this Agreement due to
Force Majeure (as defined herein).  If a
party’s performance of its obligations under this Agreement is affected by
Force Majeure, then it shall give written notice to the other party, specifying
the nature and extent of the Force Majeure, within seven (7) days of becoming
aware of the Force Majeure and will at all times use all reasonable endeavors
to mitigate the severity of the Force Majeure. 
If the Force Majeure in question prevails for a continuous period in
excess of ninety (90) days after the date on which the Force Majeure begins,
the party not in default is then entitled to give notice in

 25
 

 CONFIDENTIAL

writing to the
defaulting party to terminate this Agreement. 
The notice to terminate must specify the termination date, which must
not be less than ten (10) days after the date on which the notice to terminate
is given.  Once a notice to terminate has
been validly given, this Agreement will terminate on the termination date set
out in the notice and neither party shall be liable for any claims, damages or
penalties for such failure or delay.  For
the purposes herein, “Force
Majeure” means, in relation to either party, acts of God, acts
of war or national emergency, riots, civil commotion, terrorism, fire,
explosion, public utilities failure, or flood.

12.12      Notices.  Any notices
required or permitted hereunder shall be given to the appropriate party at the
address specified below or at such other address as the party shall specify in
writing.

If to Company:                                                                 Amylin Pharmaceuticals, Inc.

9360 Towne Centre Drive

San Diego, CA 92121

Attn:  Director
Supply Agreements & Purchasing

Fax:  (858) 824-7645

With a copy sent
to the attention of General Counsel at the same address as above, Fax:  (858) 552-1936

If to Manufacturer:                                         Wockhardt UK (Holdings) Ltd.

Ash Road North

Wrexham Industrial Estate

Wrexham LL13 9UF

United Kingdom

Attn:  Company
Secretary

Fax:  0044 1978
661676

All notices shall be deemed made upon receipt by the
addressee as evidenced by the applicable written receipt or, in the case of a
facsimile, as evidenced by the confirmation of transmission, or, in the case of
an email, as evidenced by a reply email.

12.13      Counterparts. 
This Agreement may be executed in multiple counterparts, each of which
shall be deemed an original and all of which together shall constitute one and
the same instrument.

12.14      Non-Waiver.  No failure or
delay of one of the parties to insist upon strict performance of any of its
rights or powers under this Agreement shall operate as a waiver thereof, nor
shall any other single or partial exercise of such right or power preclude any
other further exercise of any rights or remedies provided by law.

12.15      Export.  Manufacturer
agrees not to export, directly or indirectly, any U.S. source technical data
acquired from Company or any products utilizing such data to countries outside
the United States, which export may be in violation of the United States’
export laws or regulations.

 26
 

 CONFIDENTIAL

12.16      Product Liability Insurance. Manufacturer will obtain product
liability insurance to the extent Company so advises in writing.  Company will in turn reimburse Manufacturer
for such insurance premiums within thirty (30) days of the receipt of the
invoice for same.  Any product liability
claim beyond such amount will be solely on account of Company.

12.17      Cooperation with Collaboration Partner. Manufacturer acknowledges that Company
may enter into a collaborative arrangement with one or more companies (each
such company, a “Collaboration
Partner”) for the sale and marketing of product(s) containing
Pramlintide Acetate, including Product. Manufacturer agrees to cooperate with
any Collaboration Partner in all matters relating to supply for and regulatory
compliance of Product, and to permit Collaboration Partner access to all
facilities, records and information that Collaboration Partner may reasonably
request in connection therewith. Any such Collaboration Partner shall be deemed
a beneficiary of this Agreement, shall have the right to cure any breach of
this Agreement by Company, and with the consent of Company, which such consent
shall not be unreasonably withheld, may institute legal action to enforce the
terms of this Agreement.

IN WITNESS WHEREOF, the parties hereto have executed this Agreement on the Effective Date.

	
  Amylin Pharmaceuticals, Inc.

  	
   

  	
  WOCKHARDT UK
  (HOLDINGS) ltd.

  
	
   

  	
   

  
	
  By:

  	
  /s/ Daniel M.
  Bradbury

  	
   

  	
  By:

  	
  /s/ Sirjiwan Singh

  	
   

  
	
   

  	
   

  
	
  Printed Name:

  	
  Daniel M.
  Bradbury

  	
   

  	
  Printed Name:

  	
  Sirjiwan Singh

  	
   

  
	
   

  	
   

  
	
  Title:

  	
  President and
  Chief Operating Officer

  	
   

  	
  Title:

  	
  Managing Director

  	
   

  
															

 27

 CONFIDENTIAL

EXHIBIT A

Pricing

	
  Pramlintide Acetate low-dose
  1.5 ml cartridge

  	
  [***] per naked cartridge bulk packed in Correx
  trays

  
	
   

  	
   

  
	
  Pramlintide
  Acetate demonstration (Placebo) 1.5 ml cartridge

  	
  [***] per naked cartridge bulk packed in Correx
  trays

  
	
   

  	
   

  
	
  Pramlintide
  Acetate high-dose 2.7 ml cartridge

  	
  [***] per naked cartridge bulk packed in Correx
  trays

  

 

Above prices are
applicable to the following nominal batch yields which, subject to Section
4.1(b) herein, shall be re-determined in accordance with an agreed Target
Yield:

	
  Product

  	
  Batch Quantity
  (litres)

  	
  Batch Yield
  (cartridges)

  
	
   

  	
   

  	
   

  
	
  1.5ml cartridge

  	
  [***]

  	
  [***]

  
	
   

  	
   

  	
   

  
	
  2.7ml cartridge

  	
  [***]

  	
  [***]

  

 

[***] are
inclusive in the prices set forth above.

Any additional
services, such as assistance with regulatory submissions, provision of
documentation copies, non-routine quality control testing and component
approval, will be charged at a rate of [***] per man-hour.  These services and document copies are in
addition to those required to be supplied by the Manufacturer under this
Agreement.  All services and copies, and
the charges for them, must be agreed in advance by Company.

***CONFIDENTIAL
TREATMENT REQUESTED

 A-1

 CONFIDENTIAL

EXHIBIT B

Purchase
Specifications for Pramlintide Acetate Injection in Cartridges

(See attached
specifications for SYMLIN Injection 1.5mL and 2.7mL Cartridges and

SYMLIN Placebo in
Cartridges (PBO-F8))

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00117-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00117-of-00352.parquet"}]]